Chronic renal failure and new molecular marters in pediatrics Enfermedad renal crónica en pediatría y nuevos marcadores moleculares
Author
dc.contributor.author
Sch, Francisco Cano
Author
dc.contributor.author
Angélica Rojo, L.
Author
dc.contributor.author
María Luisa Ceballos, O.
Admission date
dc.date.accessioned
2019-03-11T13:19:36Z
Available date
dc.date.available
2019-03-11T13:19:36Z
Publication date
dc.date.issued
2012
Cita de ítem
dc.identifier.citation
Revista Chilena de Pediatria, Volumen 83, Issue 2, 2018, Pages 117-127
Identifier
dc.identifier.issn
03704106
Identifier
dc.identifier.issn
07176228
Identifier
dc.identifier.other
10.4067/S0370-41062012000200002
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/165676
Abstract
dc.description.abstract
Chronic Renal Failure (CRF) is associated in the mid and long-term to severe complications. New therapies have been introduced in the last decades, however some disturbances as growth failure, mineral metabolism, and anemia, among others, still remain unresolved, and long-term cardiovascular morbimortality remains unacceptable high. In recent years, new molecular markers have been introduced as promising tools in the prevention and management of uremic disturbances. Fibroblast Growth Factor23 (FGF23), Klotho, Hepcidin and growth hormone (GH) intracellular signaling are discussed in this article. FGF23, acting through Klotho protein, increases the rate of urinary excretion of phosphate and inhibits renal production of 1,25-dihydroxyvitamin D, as an important regulator of mineral metabolism. Hepcidin inhibits intestinal iron absorption and iron release from macrophages and hepatocytes; its production is increased by inflammation and high hepcidin plasma levels limit iron availability for